Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 9/2014

01-09-2014 | Psoriatic Arthritis (O FitzGerald and P Helliwell, Section Editors)

Novel Treatments with Small Molecules in Psoriatic Arthritis

Authors: Renata Baronaite Hansen, Arthur Kavanaugh

Published in: Current Rheumatology Reports | Issue 9/2014

Login to get access

Abstract

Current treatment options for patients with active psoriatic arthritis (PsA) include synthetic disease-modifying antirheumatic drugs and biologic agents. Propelled by increased understanding of immunopathogenesis of PsA, new therapeutic agents targeting different biologic pathways have been evaluated. This article discusses novel small-molecule, orally available treatments that are currently in clinical development for the treatment of psoriasis and PsA. This includes the phosphodiesterase 4 inhibitor apremilast and Janus kinase (JAK) inhibitors. Apremilast has demonstrated significant improvements in patients with moderate to severe psoriasis and PsA in phase II and III clinical trials and has recently been approved for the treatment of PsA. Tofacitinib, an oral inhibitor of JAK3, JAK1, and, to a lesser degree, JAK2, approved for the treatment of rheumatoid arthritis in several countries, has demonstrated positive results in psoriasis in phase II studies. Studies in PsA are ongoing. With these new developments, treatment options will continue to improve in the future.
Literature
1.
2.
Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33(7):1417–21.PubMed
3.
Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.PubMedCrossRef
4.
Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–26.PubMedCrossRef
5.
Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–9.PubMedCrossRef
6.
Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9.PubMedCrossRef
7.
Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.PubMedCrossRef
8.
Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–21.PubMedCrossRef
9.
Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168(2):402–11.PubMedCrossRef
10.
Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63(4):939–48.PubMedCrossRef
11.
Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.PubMedCrossRef
12.•
Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90. A good article providing a thorough description of mechanism of action of PDE4 inhibitor apremilast.PubMedCrossRef
13.
Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503–19.PubMedCrossRef
14.
Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.PubMedCrossRefPubMedCentral
15.
McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.PubMedCrossRefPubMedCentral
16.
Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738–46.PubMedCrossRef
17.
Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol. 2013;27(3):e376–83.PubMedCrossRef
18.•
Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64(10):3156–67. Important article describing a phase II study showing efficacy of apremilast in joint symptoms in patients with PsA.PubMedCrossRef
19.
Strand V, Schett G, Hu C, et al. Patient-reported health-related quality of life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol. 2013;40(7):1158–65.PubMedCrossRef
20.••
Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-6. Important article describing a phase III study on apremilast in 504 patients with PsA. Apremilast demonstrated efficacy in improving skin and joint symptoms, as well as enthesitis and dactylitis.
21.••
Cutolo M, Myerson GE, Fleischmann RM, et al. Long-term (52-week) results of a Phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2) [abstract]. Arthritis Rheum. 2013;65(Suppl):S346. This abstract describes efficacy of a apremilast in improving joint symptoms, the Health assessment questionnaire disability index, Medical Outcomes Survey Short form-36 Physical Functioning and skin at 52 weeks of treatment in a phase III study of 484 patients with PsA.
22.
Edwards CJ, Blanco FJ, Crowley J, et al. Long-term (52-week) results of a Phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3) [abstract]. Arthritis Rheum. 2013;65(Suppl):S132.
23.••
Gladman DD, Mease PJ, Kavanaugh A, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: pooled results from three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S347. This article provides a description of the efficacy of apremilast in improving dactylitis and enthesitis in PsA patients in three phase III studies.
24.•
Mease PJ, Kavanaugh A, Gladman DD, et al. Long-term safety and tolerability of apremilast, an oral phospho- diesterase 4 inhibitor, in patients with psoriatic arthritis: pooled safety analysis of three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S131. This article provides a describtion of adverse events of apremilast from three phase III studies.
25.
Mease PJ, Kavanaugh A, Adebajo AO, et al. Laboratory abnormalities in patients with psoriatic arthritis receiving apremilast, an oral phosphodiesterase 4 inhibitor: pooled safety analysis of three Phase 3, randomized, controlled trials [abstract]. Arthritis Rheum. 2013;65(Suppl):S151.
26.•
Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12(4):464–70. This article describes the mechanism of action of JAK inhibitors.PubMedCrossRefPubMedCentral
27.
Meyer SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res. 2014;20:2051-9.
28.•
Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012;167(3):668–77. This study describes the efficacy of JAK inhibitor tofacitinib in improving skin symptoms in a phase II study in patients with psoriasis.PubMedCrossRef
29.•
Mamolo C, Harness J, Tan H, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2013.doi:10.​1111/​jdv.​12081. This article describes the efficacy of JAK inhibitor tofacitinib in improving patient-reported outcomes in phase II study in patients with psoriasis.
30.
Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–60.PubMedCrossRef
31.
van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.PubMedCrossRef
32.
Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–61.PubMedCrossRef
33.•
Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510–5. A good review of adverse events of tofacitinib in RA patients.PubMedCrossRefPubMedCentral
34.
Macfarlane LA, Todd DJ. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis. 2014;17(4):359-68.
35.
Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.PubMedCrossRefPubMedCentral
36.
Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–45.PubMedCrossRefPubMedCentral
37.
Menter A, Papp K, Janes J, et al. A Phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate-to-severe psoriasis [abstract]. J Am Acad Dermatol. 2014;70(5):AB162.
38.
Ryan C, Abramson A, Patel M, et al. Current investigational drugs in psoriasis. Expert Opin Investig Drugs. 2012;21(4):473–87.PubMedCrossRef
39.
Metadata
Title
Novel Treatments with Small Molecules in Psoriatic Arthritis
Authors
Renata Baronaite Hansen
Arthur Kavanaugh
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 9/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0443-6

Other articles of this Issue 9/2014

Current Rheumatology Reports 9/2014 Go to the issue

Orphan Diseases (B Manger, Section Editor)

Pachydermodactyly: A Review

Systemic Lupus Erythematosus (M Petri, Section Editor)

Rituximab and Lupus – A Promising Pair?

SPONDYLOARTHRITIS (MA KHAN, SECTION EDITOR)

Seronegative Arthritis in Latin America: A Current Review

Pediatric Rheumatology (S Ozen, Section Editor)

Genetic Defects in Cytolysis in Macrophage Activation Syndrome

Systemic Lupus Erythematosus (M Petri, Section Editor)

Treatment of Osteonecrosis in Systemic Lupus Erythematosus: A Review

Vasculitis (L Espinoza, Section Editor)

Vasculitis in Systemic Lupus Erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits